Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.135
Filtrar
1.
Wiad Lek ; 72(7): 1274-1280, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31398155

RESUMO

OBJECTIVE: Introduction: Several studies has shown that rotaviruses play a leading role in the structure of acute intestinal infections (AII) of viral etiology in children. In the National vaccination calendar of Ukraine, vaccination against rotavirus infection (RVI) is classified as recommended, with the expected goal of reducing the number of severe RVI cases among under five-year-old children. Nevertheless, despite the positive epidemiological and clinical effects of vaccination against RVI, it remains unclear how appropriate the introduction of rotavirus vaccines is in terms of potential costs and benefits, as well as determining the optimal level of subsidy required to cover part of the costs of voluntary vaccination of the population. The aim: Study of optimal subsidy level of rotavirus vaccine in Ukraine using epidemiological and pharmacoeconomic modeling. PATIENTS AND METHODS: Materials and methods: The retrospective epidemiological data of the monthly RVI incidence in Ukraine as well as the population number from 2010 to 2016 formed the information basis for determining the transmission parameter of the viral agent. The scenario of RVI epidemic process as an acute intestinal infection from the point of view of mathematical epidemiology is best described by developed mathematical model. Cost-benefit of rotavirus vaccination was studied with the use of developed pharmacoeconomic criteria. RESULTS: Results and conclusions: Prediction of possible implications of RVI vaccination and finding optimal level of vaccine supply involves a comprehensive study of the epidemic process peculiarities of this infection with development of an adequate epidemiological model. We have proposed a model of RVI epidemiological process in Ukraine, determining its main parameters with the use of available retrospective data of anual number of RVI cases for the period from 2010 to 2016. The developed model was used as an analytical tool for analyzing influence of different levels of vaccine supply on vaccination cost-benefit. The results of research showed that the use of epidemiological modeling in pharmacoeconomic analysis of rotavirus vaccination made it possible to determine analytically optimal level of vaccination subsidy level.


Assuntos
Gastroenterite , Vacinas contra Rotavirus , Farmacoeconomia , Humanos , Estudos Retrospectivos , Ucrânia , Vacinação , Vacinas Atenuadas
2.
An Acad Bras Cienc ; 91(suppl 3): e20190208, 2019 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-31411242

RESUMO

The development of our society has been based on the use of biodiversity, especially for nutrition, medicines and beauty. Brazil is the nation with the largest biodiversity in the world, with a rich chemical diversity, which is a potential source for bioeconomy. Considering the chemical and biological diversity of the Brazilian territory, we would like to highlight the value of secondary metabolites from Brazilian biodiversity with potential application for new products and technologies and the importance of scientific programs to support the sustainable use of biodiversity.


Assuntos
Biodiversidade , Produtos Biológicos , Descoberta de Drogas , Farmacoeconomia , Plantas Medicinais/química , Brasil , Plantas Medicinais/classificação
3.
Medicine (Baltimore) ; 98(32): e16813, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31393412

RESUMO

Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis.We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VL < 50 copies/mL at week 48, and on associated adverse effects.The 177 HIV+ patients were collected, 77.4% male, with average age of 48.5 years and mean count of 252.2cell/µL CD4+ nadir lymphocytes; 96.6% had VL < 50 copies/mL and 674 cells/µL CD4+ lymphocytes. Median time since HIV diagnosis was 15 years, and median ART duration was 13 years, and 34.5% of patients were on mono- or dual-therapy before the switch. At week 48, 82.4% of patients had VL < 50 cop/µL using an intention-to-treat (ITT) analysis, 89.6% according to mITT, and 96.7% according to Per-Protocol analysis. 3.3% patients had virological failure (VF). These effectiveness data and costs were compared with those for 2 reference triple therapies (DTG/ABC/3TC and EVG/cobi/FTC/TAF) in a cost minimization analysis, showing cost savings with administration of DTG+3TC (2741 &OV0556;/year vs DTG/ABC/3TC and 4164 &OV0556;/year vs EVG/cobi/FTC/TAF) and in a cost-effectiveness analysis, finding the DT to be the most cost-effective approach (ICER = -548 vs DTG/ABC/3TC and ICER = -4,627&OV0556; vs EVG/cobi/FTC/TAF)The combination of 3TC with DTG appears to be a safe and effective option for the simplification of ART in pretreated and virologically stable HIV-positive patients, being cost-effective and offering the same effectiveness as the triple therapy it replaces.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Lamivudina/uso terapêutico , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/efeitos adversos , Fármacos Anti-HIV/economia , Contagem de Linfócito CD4 , Análise Custo-Benefício , Quimioterapia Combinada , Farmacoeconomia , Honorários Farmacêuticos/estatística & dados numéricos , Feminino , HIV-1 , Compostos Heterocíclicos com 3 Anéis/administração & dosagem , Compostos Heterocíclicos com 3 Anéis/efeitos adversos , Compostos Heterocíclicos com 3 Anéis/economia , Humanos , Lamivudina/administração & dosagem , Lamivudina/efeitos adversos , Lamivudina/economia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Carga Viral
4.
Expert Rev Pharmacoecon Outcomes Res ; 19(4): 379-381, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31159614

RESUMO

Introduction: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) organized its first Central Eastern European regional meeting in 2019 in Warsaw, Poland. Area covered: The scientific program of the two-day conference covered a broad range of topics presented from the perspective of the region. Specifically, the focus was on cross-country collaboration within different steps of health technology assessment (HTA) and the need for local HTA adaptations in decision-making. Expert commentary: Attended by approximately 200 delegates from many countries and by several high level ISPOR leaders, the conference provided a valuable opportunity to exchange knowledge and strengthen the scientific network among experts from different stakeholder groups on issues specific to the region.


Assuntos
Farmacoeconomia/organização & administração , Avaliação de Resultados (Cuidados de Saúde)/organização & administração , Avaliação da Tecnologia Biomédica/organização & administração , Custos e Análise de Custo , Tomada de Decisões , Europa Oriental , Humanos , Agências Internacionais , Cooperação Internacional
6.
Issue Brief (Commonw Fund) ; 2019: 1-8, 2019 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-30883061

RESUMO

Issue: The German health care system resembles that of the United States in important ways ­ it is financed by multiple private payers and relies principally on negotiation rather than regulation to establish prices. New drugs that offer minimal benefits compared with existing alternatives within a therapeutic class are subject to reference pricing; those with incremental benefits are subject to price negotiations. Together, the reference and negotiated pricing systems have held German prices substantially below U.S. equivalents. Goal: To describe the German reference-pricing system and compare it to tiered formularies and consumer cost-sharing in the United States. Methods: Document review and interviews with leaders in payer, policy, and pharmaceutical industry organizations in Germany. Key Findings and Conclusions: The German pharmaceutical pricing system uses modest levels of consumer cost-sharing to influence consumers' choices for drugs with therapeutically equivalent alternatives. Manufacturers are free to set the prices of their products, but insurers will not pay more for a new drug than for its comparators unless it offers an additional clinical benefit. For drugs covered by reference pricing, the insurers' payment maximum is set at a level that ensures sufficient choices of low-priced options. These models offer an alternative to the U.S. system of tiered formularies.


Assuntos
Custo Compartilhado de Seguro/economia , Custos e Análise de Custo , Custos de Medicamentos , Farmacoeconomia , Seguro de Serviços Farmacêuticos/economia , Pesquisa Comparativa da Efetividade , Indústria Farmacêutica/economia , Formulários Farmacêuticos como Assunto , Alemanha , Humanos , Negociação , Equivalência Terapêutica , Estados Unidos
8.
Expert Rev Pharmacoecon Outcomes Res ; 19(4): 421-430, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30722711

RESUMO

INTRODUCTION: Innovative drugs have been approved in ophthalmology. Thus, the number and importance of economic evaluation studies of ophthalmic drugs have been growing. This study aims to assess the methodological quality of pharmacoeconomic studies of ophthalmic drugs. AREAS COVERED: A systematic search was conducted in Pubmed/Embase until November 2018 to identify full pharmacoeconomic studies evaluating ophthalmic drugs. The quality of studies was evaluated using the British Medical Journal (BMJ) checklist. Quality indicators were evaluated by Fisher's exact test. Ninety-five studies were included, 50 (52.6%) cost-utility analysis, 28 (29.5%) cost-effectiveness and 17 (17.9%) cost-effectiveness/cost-utility. All studies presented, at least, three methodological limitations. Cost-utility studies, studies conducted from a health system perspective, with time horizons longer than one-year and that rely on observational or observational and experimental data simultaneously are associated with higher quality. Only eight (8.4%) studies considered two eyes in the economic analysis and only 13 (13.7%) considered the natural history of the disease when extrapolating results for long-term analysis. EXPERT OPINION: The majority of the pharmacoeconomic studies were assessed as having good methodological quality, however, the methodological quality scores were sensitive to several indicators. Therefore, improving the quality of studies would enhance their usefulness in the decision-making processes.


Assuntos
Farmacoeconomia , Oftalmopatias/tratamento farmacológico , Projetos de Pesquisa , Administração Oftálmica , Lista de Checagem , Análise Custo-Benefício , Tomada de Decisões , Aprovação de Drogas , Oftalmopatias/economia , Humanos , Indicadores de Qualidade em Assistência à Saúde
9.
Duke Law J ; 68(4): 767-805, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30649837

RESUMO

Bacteriophages, or "phages," are a category of highly adept and adaptable viruses that can infect and kill bacteria. With concerns over the burgeoning antibiotic-resistance crisis looming in recent years, scientists and policymakers have expressed a growing interest in developing novel treatments for bacterial infections that utilize bacteriophages. Because of the great expense associated with bringing a new drug to market, patents are usually considered the gold standard for incentivizing research and development in the pharmaceutical field. Absent such strong protection for a developer's front end investment, pharmaceutical development remains financially risky and unattractive. Unfortunately, recent Supreme Court jurisprudence analyzing patentable subject matter under 35 U.S.C. subsection 101 has cast doubt on whether phage therapeutics would be eligible for strong patent protection. In order for the promise of phage therapeutics to become a reality, alternative protections or incentives are likely necessary. Such a framework would likely include trade secrecy, regulatory exclusivities, research support, alternative payment models, or some combination thereof.


Assuntos
Aprovação de Drogas/economia , Aprovação de Drogas/legislação & jurisprudência , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/legislação & jurisprudência , Farmacorresistência Bacteriana Múltipla , Farmacoeconomia/legislação & jurisprudência , Patentes como Assunto/legislação & jurisprudência , Terapia por Fagos/economia , Pesquisa/economia , Pesquisa/legislação & jurisprudência , Bacteriófagos , Competição Econômica/legislação & jurisprudência , Humanos , Motivação , Estados Unidos
10.
J Manag Care Spec Pharm ; 25(2): 260-271, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30698084

RESUMO

BACKGROUND: Pharmacogenetic testing can provide predictive insights about the efficacy and safety of drugs used in cancer treatment. Although many drug-gene associations have been reported in the literature, the strength of evidence supporting each association can vary significantly. Even among the subgroup of drugs classified by the PharmGKB database to have a high or moderate level of evidence, there is limited information regarding the economic value of pharmacogenetic testing. OBJECTIVES: To: (a) summarize the available pharmacoeconomic evidence assessing the value of pharmacogenetic testing for cancer drugs with clinically relevant drug-gene associations; (b) determine the quality of the studies that contain this evidence; and (c) discuss the quality of this evidence with respect to the level of evidence of the drug-gene associations. METHODS: The PharmGKB database was used to identify cancer drugs with clinically relevant drug-gene associations graded high (1A, 1B) or moderate (2A, 2B). A systematic literature review was conducted using these drugs. Ovid MEDLINE and Embase databases were searched to identify cost-effectiveness, cost-utility, or cost-minimization studies comparing pharmacogenetic testing to an alternative. Cost and effect values from every relevant comparison within the studies were extracted, and the incremental cost-effectiveness ratio (ICER) was either extracted or calculated for each comparison. Quality assessment was conducted for each study using the Quality of Health Economic Studies (QHES) instrument. Qualitative synthesis was used to summarize the data. RESULTS: The search yielded 2,191 citations, of which 35 studies met the inclusion criteria. Pharmacoeconomic studies were available for the following drugs from the PharmGKB database: fluoropyrimidine, 6-mercaptopurine, irinotecan, carboplatin, cisplatin, erlotinib, gefitinib, cetuximab, panitumumab, and trastuzumab. The studies were conducted in Asia, Europe, Canada, the United States, and Mexico and reported cost-utility, cost-effectiveness, and cost-minimization outcomes. The mean QHES score was 80 (SD = 22) for the studies of drug-gene pairs with high (1A, 1B) and moderate (2A, 2B) levels of evidence (1A = 82, 1B = 93, 2A = 71, and 2B = 74). There was variation across studies in terms of reporting. 109 relevant comparisons were identified within the studies. Of those that reported cost per life-year or cost per quality-adjusted life-year (n = 58 comparisons), pharmacogenetic testing was dominant in 21% overall and 42%, 21%, 17%, and 5% of the comparisons in Asia, Europe, Canada, and the United States, respectively. Variability was observed in the ICER values regardless of geographic region or drug. Pharmacogenetic testing was cost saving in 17 of 19 cost-minimization comparisons and was favored most frequently when compared with genetically indiscriminate strategies containing the drug of interest. CONCLUSIONS: There was mixed evidence regarding the value of pharmacogenetic testing to guide cancer treatment. For future pharmacogenomic-related economic studies, we recommend prioritizing clinically relevant drug-gene associations and greater adherence to available best practice guidelines for conducting and reporting economic evaluation studies. DISCLOSURES: No outside funding supported this review. Part of Hussain's research time was supported by a Merit Review Award (I01 BX000545), Medical Research Service, U.S. Department of Veterans Affairs. Hussain also reports personal fees from Bristol-Myers Squibb, AstraZeneca, Novartis, Bayer HealthCare Pharmaceuticals, and France Foundation, outside the submitted work. Onukwugha reports grants from Pfizer and Bayer HealthCare Pharmaceuticals, along with advisory board fees from Novo Nordisk, outside the submitted work. Faruque, Neuberger, and Noh have nothing to disclose.


Assuntos
Antineoplásicos/economia , Farmacoeconomia , Testes Farmacogenômicos/economia , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Análise Custo-Benefício , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/genética , Anos de Vida Ajustados por Qualidade de Vida
11.
Int J Clin Pharm ; 41(1): 74-80, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30552622

RESUMO

Background The emergence and rapid spread of multidrug-resistant gram-negative bacteria related to nosocomial infections is a growing worldwide problem, and polymyxins have become important due to the lack of new antibiotics. Objectives To evaluate the outcomes and pharmacoeconomic impact of using colistin and polymyxin B to treat nosocomial infections. Setting Neurosurgical, cardiovascular, or transplantation intensive care unit (ICU) at the Clinical Hospital of the University of Campinas (São Paulo, Brazil). Method A retrospective cohort study was conduct in patients in the ICU. The renal function was determined daily during treatment by measuring the serum creatinine. A cost minimization analysis was performed to compare the relative costs of treatment with colistin and polymyxin B. Main outcomes measure The outcomes were 30-day mortality and frequency and onset of nephrotoxicity after beginning treatment. Results Fifty-one patients treated with colistin and 51 with polymyxin B were included. 30-day mortality was observed in 25.49% and 33.33% of patients treated with colistin and polymyxin B, respectively; Nephrotoxicity was observed in 43.14% and 54.90% of patients in colistin and polymyxin B groups, respectively; and onset time of nephrotoxicity was 9.86 ± 13.22 days for colistin and 10.68 ± 9.93 days for polymyxin B group. Colistin treatment had a lower cost per patient compared to the cost for polymyxin B treatment (USD $13,389.37 vs. USD $13,639.16, respectively). Conclusion We found no difference between 30-day mortality and nephrotoxicity between groups; however, colistin proved to be the best option from a pharmacoeconomic point of view.


Assuntos
Antibacterianos/economia , Colistina/economia , Infecção Hospitalar/economia , Farmacoeconomia , Unidades de Terapia Intensiva/economia , Polimixina B/economia , Adulto , Idoso , Antibacterianos/uso terapêutico , Brasil/epidemiologia , Estudos de Coortes , Colistina/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/epidemiologia , Custos de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Polimixina B/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento
13.
Value Health Reg Issues ; 17: 219-223, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30528780

RESUMO

In February and September of 2017, the International Society for Pharmacoeconomics and Outcomes Research Health Technology Assessment Council held roundtables focused on Latin America to discuss health technology assessment best practices, collaboration opportunities, and regional experiences regarding health policies to improve the affordability of and access to healthcare technologies. The access to high-cost technologies, increased social pressure to achieve universal coverage, population aging, and the limits of traditional mechanisms to control costs create political pressure to begin considering other pricing alternatives, including value-based pricing, in Latin America. This article attempts to conceptualize key stakeholders' perceptions of their experiences, opportunities, and barriers to implementing value-based pricing in Latin America.


Assuntos
Custos e Análise de Custo , Farmacoeconomia/tendências , Avaliação da Tecnologia Biomédica/tendências , Cobertura Universal do Seguro de Saúde/tendências , Envelhecimento , Tecnologia Biomédica/economia , Política de Saúde , Humanos , América Latina
14.
15.
JAMA ; 320(16): 1710-1711, 2018 10 23.
Artigo em Inglês | MEDLINE | ID: mdl-30357291
16.
Issue Brief (Commonw Fund) ; 2018: 1-6, 2018 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-30199167

RESUMO

Issue: Reference pricing is an emerging health insurance benefit design aimed at reducing health costs. In this model, an insurer establishes a maximum payment that it will contribute toward covering the price of a product or service in situations where there is wide price variation for therapeutically similar drugs, diagnostics, or procedures. Experiences to date indicate that reference pricing can influence patients and physicians to switch to less costly options within each therapeutic class, reducing overall drug prices. Goal: Describe how reference pricing can be and has been applied to drugs in the United States and compare it to more conventional pharmaceutical benefit designs such as tiered formularies and coinsurance. Methods: Assessment of peer-reviewed research and the experiences of employers that have used reference pricing. Findings and Conclusions: To appropriately motivate price-conscious consumer choice, reference pricing must include up-to-date information. Consumers and physicians must have access to the prices charged at different distribution sites and for different drugs within each therapeutic class. Reference pricing also must include information on quality. Several modifications to the reference pricing model should be made before it can be adapted to specialty drugs, and those changes should be informed by comparative effectiveness research.


Assuntos
Custos e Análise de Custo/economia , Custos de Medicamentos , Farmacoeconomia , Pesquisa Comparativa da Efetividade , Controle de Custos , Redução de Custos , Formulários Farmacêuticos como Assunto , Humanos , Equivalência Terapêutica , Estados Unidos
17.
NCSL Legisbrief ; 26(29): 1-2, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30199170

RESUMO

(1) At least 74.7 million Americans use three or more prescription drugs in a 30-day period. (2) Eighty percent of the U.S. public views prescription drug costs as "unreasonable," while 17 percent say "reasonable," according to a recent poll. (3) An influenza drug has a cash price of $100, but a patient with insurance may pay $125 because of a "gag clause" that restricts pharmacists from disclosing price options.


Assuntos
Custos de Medicamentos/legislação & jurisprudência , Farmacoeconomia/legislação & jurisprudência , Medicamentos sob Prescrição/economia , Governo Estadual , Revelação/legislação & jurisprudência , Medicamentos Genéricos/economia , Governo Federal , Humanos , Marketing de Serviços de Saúde/economia , Marketing de Serviços de Saúde/legislação & jurisprudência , Uso Off-Label/economia , Uso Off-Label/legislação & jurisprudência , Estados Unidos
18.
Rev. enferm. Inst. Mex. Seguro Soc ; 26(4): 239-247, Septiembre-Dic. 2018. graf, tab
Artigo em Espanhol | LILACS, BDENF - Enfermagem | ID: biblio-970136

RESUMO

Objetivo: determinar el impacto económico institucional del programa Receta Resurtible con pacientes diabéticos. Material y métodos: estudio de costos antes y después del programa Receta Resurtible con pacientes diabéticos. El costo promedio incluyó perfil de uso y costo unitario. El perfil de uso se determinó para Consulta externa, Farmacia y medicamentos. En el análisis se plantearon escenarios y se adoptaron supuestos. Resultados: el promedio de consultas antes y después se ubica en 6.45 y 4.73, respectivamente. La dotación de medicamentos fue 55.8% y 99%. El impacto del programa para una unidad de medicina familiar con 6400 pacientes diabéticos, de los cuales 18% se encuentra en el programa Receta Resurtible, permite un ahorro de $ 490 366 en la consulta de Medicina familiar y atención en Farmacia, sin embargo existe un incremento de $112 100 por consumo de medicamentos, el ahorro total en este escenario es de $378 266. Conclusión: el impacto económico del programa Receta Resurtible es benéfico para la institución.


Objective: To determine the institutional economic impact of the Resupply Prescription program in diabetic patients. Material and methods: Study of costs before and after the Resupply Prescription program with diabetic patients. The average cost included usage profile and unit cost. The profile of use was determined for External consultation, Pharmacy and medication. In the analysis, scenarios were raised and assumptions were adopted. Results: The average of before and after consultations is located at 6.45 and 4.73, respectively. The medication provision was 55.8 and 99%. The impact of the program for a Family Medicine Unit with 6400 diabetic patients, of which 18% is in the Resupply Prescription program, allows a saving of $ 490 366 in the consultation of Family Medicine and Pharmacy, however there is a increase of $ 112 100 for drug consumption, the total saving in this scenario is $ 378 266. Conclusion: The economic impact of the Resupply Prescription program is beneficial for the institution.


Assuntos
Humanos , Prescrições de Medicamentos , Atenção Primária à Saúde , Avaliação de Programas e Projetos de Saúde , Farmacoeconomia , Diabetes Mellitus , Economia , Economia Médica , Prescrições , México
19.
Rev. enferm. Inst. Mex. Seguro Soc ; 26(4): 232-238, Septiembre-Dic. 2018. graf, tab
Artigo em Espanhol | LILACS, BDENF - Enfermagem | ID: biblio-979898

RESUMO

Objetivo: determinar el impacto económico institucional del programa Receta Resurtible con pacientes diabéticos. Material y métodos: estudio de costos antes y después del programa Receta Resurtible con pacientes diabéticos. El costo promedio incluyó perfil de uso y costo unitario. El perfil de uso se determinó para Consulta externa, Farmacia y medicamentos. En el análisis se plantearon escenarios y se adoptaron supuestos. Resultados: el promedio de consultas antes y después se ubica en 6.45 y 4.73, respectivamente. La dotación de medicamentos fue 55.8% y 99%. El impacto del programa para una unidad de medicina familiar con 6400 pacientes diabéticos, de los cuales 18% se encuentra en el programa Receta Resurtible, permite un ahorro de $ 490 366 en la consulta de Medicina familiar y atención en Farmacia, sin embargo existe un incremento de $112 100 por consumo de medicamentos, el ahorro total en este escenario es de $378 266. Conclusión: el impacto económico del programa Receta Resurtible es benéfico para la institución.


Objective: To determine the institutional economic impact of the Resupply Prescription program in diabetic patients. Material and methods: Study of costs before and after the Resupply Prescription program with diabetic patients. The average cost included usage profile and unit cost. The profile of use was determined for External consultation, Pharmacy and medication. In the analysis, scenarios were raised and assumptions were adopted. Results: The average of before and after consultations is located at 6.45 and 4.73, respectively. The medication provision was 55.8 and 99%. The impact of the program for a Family Medicine Unit with 6400 diabetic patients, of which 18% is in the Resupply Prescription program, allows a saving of $ 490 366 in the consultation of Family Medicine and Pharmacy, however there is a increase of $ 112 100 for drug consumption, the total saving in this scenario is $ 378 266. Conclusion: The economic impact of the Resupply Prescription program is beneficial for the institution.


Assuntos
Humanos , Prescrições de Medicamentos , Atenção Primária à Saúde , Avaliação de Programas e Projetos de Saúde , Farmacoeconomia , Custos e Análise de Custo , Diabetes Mellitus , Economia , Economia Médica , Programas Nacionais de Saúde , México
20.
J. bras. econ. saúde (Impr.) ; 10(2): 134-139, Agosto/2018.
Artigo em Português | LILACS, ECOS | ID: biblio-915089

RESUMO

Objetivo: Avaliar a utilização clínica da dexmedetomidina e o custo econômico de sua aquisição em pacientes adultos em um hospital universitário. Métodos: Estudo observacional e descritivo do tipo prospectivo, em que foram analisados os formulários de solicitações do medicamento entre 15 de dezembro de 2016 e 15 de dezembro de 2017. Os dados coletados foram idade, gênero, dias solicitados e liberados, justificativa clínica, dose, posologia e via de administração. O custo financeiro foi calculado considerando o valor unitário do medicamento. A análise estatística foi realizada pelo STATA12.0. Resultados: Foram coletados 79 formulários; 14 foram da UTI cardiológica, 41, da UTI de adulto e 24, do centro cirúrgico. As solicitações foram separadas em grupos cirúrgico e clínico. Foi observada prevalência de pacientes com idade acima de 30 anos e sexo masculino. No grupo cirúrgico, o tempo médio de solicitação e liberação foi igual, enquanto no grupo clínico foi de 3,73 e 3 dias, respectivamente. A dose diária foi de 233,33 mcg/dia no grupo cirúrgico e de 773,77 µg/dia no clínico. No grupo cirúrgico, o uso foi para sedação em plástica mamária não estética; no grupo clínico, foi para agitação psicomotora, sedoanalgesia e delirium. O custo no grupo clínico foi de R$ 58.470,65, enquanto no grupo cirúrgico foi de R$ 2.995,65, totalizando R$ 61.466,30. Conclusão: O custo econômico encontrado com o uso do medicamento foi similar ao achado em outro hospital público de alta complexidade.


Objective: Evaluate clinical dexmetomidine use and economic impact of its acquisition to adult patients at a university hospital. Methods: Observational and descriptive study, of prospective type, in which the medication request forms received between December 15th, 2016 and December 15th, 2017 were analized. The data collected were age, gender, days requested and released, clinical justification, dosage, posology and method of administration. The financial cost was calculated assuming the unitary value of the medicine. The statistical analysis was performed by Stata 12.0. Results: 79 forms were collected. 14 were from the coronary care unit, 41 from the adult intensive care unit and 24 from the surgery center. The requests were divided into surgical group and clinical group. Most patients were male aged 30 or more. For the surgical group, the request and release time were mostly the same, meanwhile for the clinical one it was 3.73 and 3 days, respectively. The daily dosage was 233.33 mcg/day in the surgical group and 773.77 µg/day in the clinical one. In the surgical group the use was due to sedation in non-aesthetic breast surgeries. In the clinical one it was for psychomotor agitation, sedoanalgesia and delirium. The cost for the clinical group was R$ 58,470.65, while for the surgical one it was R$ 2,995,65, summing up R$ 61,466.30. Conclusion: The financial cost demanded with the use of the medicine was similar to the one found in another high complexity public hospital.


Assuntos
Humanos , Dexmedetomidina , Uso de Medicamentos , Farmacoeconomia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA